OR-CIRCLE-MEDIA
22.11.2016 10:02:07 CET | Business Wire | Press release
Circle Media Inc., a company leading the way in healthy screen time management across all devices, today announced two new retail partnerships that bring Circle with Disney to 10 European countries. Working with Tura and Bullboat Distribution, consumers in the United Kingdom, Germany, France, Spain, Switzerland, Sweden, Norway, Finland, Iceland and Denmark will now have the ability to integrate Circle into their homes to help parents stay informed about their kids’ online activities and limit screen time on every device in the home including smartphones, tablets, computers, and gaming consoles.
“Managing kids on devices isn't just a U.S. thing, it’s a global issue,” said Jelani Memory, founder, Circle. “Whether you're in the UK or Norway, you'll find parents who are looking for ways to manage their kids’ content and screen time. Circle is that answer.”
Circle with Disney is managed through a companion iOS app and pairs with Wi-Fi, giving parents the ability to filter content, set a bedtime for devices, and even completely pause the Internet. Each user’s profile and settings can be completely customized based on age and parents’ preferences.
Additional Information About Circle with Disney
Circle is a complete solution that helps families filter content, manage screen time, and stay informed with what their kids do online. The full suite of Circle tools includes:
CIRCLE WITH DISNEY: a smart network device that “talks” wirelessly with a home router and each household device continuously to filter and deliver content based on family settings.
CIRCLE HOME APP: the companion app for Circle with Disney gives parents the ability to filter content, set a bedtime for devices, and even completely pause the Internet. Parents can manage user profiles and settings, and completely customize them based on kids’ ages and parents’ preferences.
MYCIRCLE APP: A content dashboard for every member of the family, the MyCircle experience is tailored to each person’s interest. Family members will default to MyCircle as their homepage, which will be populated with curated and exclusive content and provide information about the user’s online history.
CIRCLE GO: Extends the Circle experience to keep all family settings active wherever the family’s devices travel. Circle Go is available for a monthly subscription of $9.95 and covers up to ten devices.
Circle with Disney will be available at a variety of retailers with pricing reflecting appropriate currencies. The Circle Home app can be downloaded for free for iOS or Android from the Apple App Store or Google Play.
About Circle Media Inc.
Founded in 2014 and with offices in Portland, Ore. and Cypress, CA, Circle Media Inc. exists to develop family-centric products that redefine how we connect. www.meetcircle.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20161122005282/en/
Contact:
Greenroom Social
Patrick Gevas, 305-347-1787 Ext. 303
Vice
President
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom